Compare Amgen, Inc. (AMGN) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Clear Secure Inc — how do they compare? Amgen, Inc. trades at $356.55 (market cap $196.12B), while Clear Secure Inc trades at $53.46 (market cap $5.56B). The key difference: Amgen, Inc. is far larger — about 35.3× Clear Secure Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | YOU | |
|---|---|---|
Market Cap | $196.12B | $5.56B |
Sector | Health | Technology |
52-Week High | $388.16 | $62.36 |
52-Week Low | $271.18 | $28.38 |
Enterprise Value | $241.41B | $4.88B |
Dividend Yield | 2.77% | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Clear Secure (YOU) trades at $55.22, down 1.6% on the day, with a bullish technical signal from moving averages and strong fundamental growth. Recent earnings beat expectations in Q1 2026, and the company expanded services with AWS integration and new airport launches. Revenue reached $900.78M in 2025, with net income of $109.17M and robust cash flow from operations of $372.45M.
Outlook remains positive due to earnings momentum and strategic expansions, but risks include high valuation multiples and competitive pressures. Analyst consensus is mixed with a $56.67 price target, suggesting moderate upside potential from current levels amid balanced sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
